Search - tctmd.com

Displaying 321 - 340 of 458

Sort: Relevancy | Date

Presentation TCT 2013

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

Presenter: Bo Xu, Yuejin Yang, Yaling Han, Bao Li, Qiang Liu, Guoying Zhu, Junyu Cui, Lang Li, Shuzheng Lu

January 31, 2013

Presentation TCT 2013

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Presenter: Peter Smits, A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet

January 31, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Industry News

Abbott Initiates Clinical Trial of Absorb™ in the United States

January 07, 2013

News Industry News

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

January 02, 2013

News Daily News

EES Outperform First-Generation DES in Treatment of CTOs

L.A. McKeown

December 27, 2012

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

Presentation

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Presenter: K. W. Park

December 25, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

News Conference News TCT 2012

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

October 25, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

News Conference News TCT 2012

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

Presentation TCT 2012

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Presenter: James Hermiller Jr

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

Advertisement

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Abbott Initiates Clinical Trial of Absorb™ in the United States

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

EES Outperform First-Generation DES in Treatment of CTOs

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Several Trials Highlight DES Comparisons

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content